The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021–2025 State‐of‐the‐Art Review of Clinical and Preclinical Evidence
Pharmacology Research & Perspectives · 2026-06 · 14 (3)
DOI: 10.1002/prp2.70280 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 07.06.2026. Verfasst von Luigi Maria Chiatto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher, Messina, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Parkinson Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Statins, widely prescribed for cardiovascular prevention, have emerged as potential disease‐modifying agents in neurodegenerative disorders due to their pleiotropic effects on cholesterol metabolism, neuroinflammation, oxidative stress, and protein aggregation. Over the past decade, growing interest has focused on the potential repurposing of statins for Parkinson's disease (PD) and Alzheimer's disease (AD); however, clinical evidence remains heterogeneous and, in some cases, contradictory. This state‐of‐the‐art review synthesizes clinical and preclinical studies published between 2021 and 2025 to critically evaluate the therapeutic potential and limitations of statins in PD and AD. Recent observational studies and large‐scale cohort analyses suggest that long‐term statin use may be associated with a reduced risk of incident PD and AD, as well as slower cognitive decline in selected patients' subgroups. However, these associations appear to depend on factors such as statin lipophilicity, treatment duration, and genetic background. Preclinical models provide mechanistic support, showing that statins can attenuate neuroinflammation, modulate microglial activation, reduce α‐synuclein aggregation in PD models, and interfere with amyloid‐β production and tau phosphorylation in AD models. Nevertheless, randomized controlled trials remain limited in number and often underpowered, and some reports indicate neutral or even adverse neurological outcomes, underscoring the complexity of cholesterol‐dependent and cholesterol‐independent mechanisms in the central nervous system (CNS). Collectively, the evidence from 2021 to 2025 highlights both the therapeutic promise and the unresolved challenges of statin repurposing in neurodegenerative diseases. Future research should prioritize well‐designed clinical trials and biomarker‐driven patient stratification to determine whether statins can be effectively leveraged as adjunctive disease‐modifying therapies in PD and AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Independent Researcher, Messina, Italy.
- Departmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
- IRCCS San Camillo Hospital, Venice, Italy.
- Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
- IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy.
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
ORCID-Profile: Rocco Salvatore Calabrò, Emanuela Esposito
Zitieren
APA
Chiatto, L. M., Buccarello, L., Carota, G., Calabrò, R. S., Rifici, C., Esposito, E., Ardizzone, A., & Caruso, G. (2026). The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021–2025 State‐of‐the‐Art Review of Clinical and Preclinical Evidence. Pharmacology Research & Perspectives, 14(3). https://doi.org/10.1002/prp2.70280
Vancouver
Chiatto LM, Buccarello L, Carota G, Calabrò RS, Rifici C, Esposito E, et al. The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021–2025 State‐of‐the‐Art Review of Clinical and Preclinical Evidence. Pharmacology Research & Perspectives. 2026;14(3). doi:10.1002/prp2.70280
BibTeX
@article{Chiatto2026,
author = {Chiatto, Luigi Maria and Buccarello, Lucia and Carota, Giuseppe and Calabrò, Rocco Salvatore and Rifici, Carmela and Esposito, Emanuela and Ardizzone, Alessio and Caruso, Giuseppe},
title = {The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021–2025 State‐of‐the‐Art Review of Clinical and Preclinical Evidence},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {3},
doi = {10.1002/prp2.70280}
}
EUVIMED